Drug – bio-affecting and body treating compositions – Radionuclide or intended radionuclide containing; adjuvant... – Attached to antibody or antibody fragment or immunoglobulin;...
Patent
1995-03-23
1998-04-07
Eisenschenk, Frank C.
Drug, bio-affecting and body treating compositions
Radionuclide or intended radionuclide containing; adjuvant...
Attached to antibody or antibody fragment or immunoglobulin;...
4241781, 424 93, 424 934, 530400, 530402, 530367, 5303913, 5303915, 5483037, A61K 5100, C07K 1600
Patent
active
057361193
ABSTRACT:
Improved methods of detecting and/or treating lesions in a patient are provided. The improved methods comprise the steps of (a) parenterally injecting a subject with a targeting composition comprised of a conjugate of biotin and targeting protein or of an avidin and targeting protein, wherein the targeting protein preferentially binds to a marker substance produced or associated with the targeted lesion, and allowing the targeting protein conjugate to preferentially accrete at the targeted lesion; (b) then parenterally injecting a clearing composition comprised of (i) avidin, when the targeting composition is a biotin-targeting protein conjugate, or (ii) biotin, when the targeting composition is a avidin-targeting protein conjugate, and allowing the clearing composition to substantially clear the targeting composition from non-targeted sites and to bind to the targeting composition accreted at the targeted lesion; (c) parenterally injecting a localization agent which may be the same or different form the clearing agent; (d) parenterally injecting a detection or therapeutic composition comprised of a conjugate of (i) avidin and naturally occurring metal-ion chelating protein chelated with chelatable metal detection or therapeutic agent when the clearing composition is biotin, or (ii) biotin and naturally occurring metal-ion carry protein chelated with chelatable a metal detection or therapeutic agent when the clearing agent is avidin, and allowing the composition to accrete at the targeted lesion. The improvement is that the use of the chelating protein to chelate a chelatable metal therapeutic or detection agent amplifies the amount of detection or therapeutic agent at the targeted site.
REFERENCES:
patent: 4732864 (1988-03-01), Tolman
patent: 4782840 (1988-11-01), Martin et al.
patent: 4863713 (1989-09-01), Goodwin et al.
patent: 4932412 (1990-06-01), Goldenberg
patent: 5443813 (1995-08-01), Hainfield
Osband et al., Immunol. Today, 11:193, 1990, Problems . . . immunotherapy.
Hird et al., Cancer & Genes, 1989, pp. 183-189, Immunotherapy . . . Antibodies.
Harris et al, Tibtech, 11:42, 1993, Therapeutic . . . Age.
Hainfeld et al., PNAS, 89:11064, 1992, Uranium . . . therapy.
Spooner et al., Tibtech, 1990, 8:189.
Paganelli et al., Nucl. Med. Comm., 1991, 12:211.
Goodwin, D. A. et al., "Pre-Targeted Immunoscintigraphy of Murine Tumors with Indium-111-Labeled Bifunctional Haptens", The Journal of Nuclear Medicine, 29:226-234 (1988).
Hnatowich, D. J. et al., "Investigations of Avidin and Biotin for Imaging Applications", The Journal of Nuclear Medicine, 2B:1294-1302 (1987).
Oehr, P. et al., "Streptavidin and Biotin as Potential Tumor Imaging Agents", The Journal of Nuclear Medicine, 29:728-729 (May 1988).
Klibanov, A. L. et al., "Blood Clearance of Radiolabeled Antibody: Enhancement by Lactosamination and Treatment with Biotin-Avidin or Anti-Mouse IgG Antibodies", The Journal of Nuclear Medicine, 29: No. 12, 1951-1956 (Dec. 1988).
Sinitsyn, V. V. et al., "Rapid Blood Clearance of Biotinylated IgG After Infusion of Avidin", The Journal of Nuclear Medicine, 30:66-69 (1989).
Schechter, B. et al., "Indirect Immunotargeting of CIS-PT to Human Epidermoid Carcinoma KB Using the Avidin-Biotin System", Int. J. Cancer: 48, 167-172 (1991).
Paganelli, G. et al., "Three-Step Monoclonal Antibody Tumor Targeting in Carcinoembryonic Antigen-positive Patients", Cancer Research, 51, 5960-5966 (Nov. 1, 1991).
Paganelli, G. et al., "Monoclonal Antibody Pretargeting Techniques for Tumour Localization: The Avidin-biotin System", Nuclear Medicine Communications 12, 211-234 (1991).
Stickney, D. R., "Bifunctional Antibody: A Binary Radiopharmaceutical Delivery System for Imaging Colorectal Carcinoma", Cancer Research 51, 6650-6655 (Dec. 15, 1991).
Yuan, Fan, "Pharmacokinetic Analysis of Two-Step Approaches Using Bifunctional and Enzyme-conjugated Antibodies", Cancer Research, 51, 3119-3130 (Jun. 15, 1991).
Paganelli, G., "In Vivo Labeling of Biotinylated Monoclonal Antibodies by Radioactive Avidin: A Strategy to Increase Tumor Radiolocalization", Int. J. Cancer: Supplement 2, 121-125 (1988).
Kalofonos, H. P. et al., "Imaging of Tumor in Patients with Indium-111-Labeled Biotin and Streptavidin-Conjugated Antibodies: Preliminary Communication", Journal of Nuclear Medicine, 31:1791-1796 (1990).
Paganelli, P. et al., "Tumor Targeting in Patients with Ovarian Cancer Using Biotinylated Monoclonal Antibodies and Radioactive Streptavidin", Scientific Papers, Proceedings of the 37th Annual Meeting, vol. 31, No. 5 (May 1990).
Hainfeld, J. F., "Uranium-loaded Apoferritin with Antibodies Attached: Molecular Design for Uranium Neutron-capture Therapy", Proc. Natl. Acad. Sci. USA, vol. 89, 11064-11068 (Nov. 1992).
Goldenberg David Milton
Griffiths Gary L.
Hansen Hans J.
Eisenschenk Frank C.
Immunomedics Inc.
LandOfFree
Detection and therapy of lesions with biotin/avidin-metal chelat does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Detection and therapy of lesions with biotin/avidin-metal chelat, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Detection and therapy of lesions with biotin/avidin-metal chelat will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-10194